FDA Issues Technical Amendments to Align with QMSR 

The U.S. Food and Drug Administration (FDA) has published a final rule implementing technical amendments across multiple parts of Title 21 of the Code of Federal Regulations (CFR) to ensure consistency with the Quality Management System Regulation (QMSR) finalized earlier this year. These changes are editorial in nature and do not impose any new requirements on medical device manufacturers.

To learn more about MedEnvoy’s QMSR services, click here.

Why This Matters

On February 2, 2024, the FDA issued the QMSR Final Rule, replacing the long-standing Quality System Regulation (QSR) with a framework harmonized to ISO 13485:2016. The QMSR becomes effective on February 2, 2026. Today’s technical amendments update references throughout existing device regulations to reflect this transition.

Key Highlights of the FDA Technical Amendments 

• Scope of Changes: 
  • 179 sections across 18 parts of Title 21 CFR have been revised.  
  • Updates primarily involve replacing references to QSR provisions with equivalent QMSR citations. 

• Examples of Updates: 
  • References to §§ 820.180 and 820.198 (Records and Complaint Files under QSR) are updated to § 820.35 (Control of Records) under QMSR. 
  • References to § 820.30 (Design Controls) now point to § 820.10(c) (Design and Development) under QMSR. 
  • Language changes from “quality system regulation” to “quality management system regulation” for consistency. 

• Device Classification Adjustments: 
  • For certain Class I devices, exemptions from most QMSR requirements remain, except for recordkeeping under § 820.35. 
  • Nine Class II device classifications now reference QMSR design and development requirements. 

• Clarifications: 
  • Authority citations corrected for clarity (e.g., italicizing “l” in 21 U.S.C. 360l). 
  • Minor typographic and wording standardizations across sections. 

Impact on Manufacturers 

• No New Compliance Obligations: 
  These amendments do not introduce new regulatory requirements. They simply align existing regulations with the QMSR terminology and structure, which was presented in previous announcements from FDA. 

• Effective Date: 
  All changes take effect February 2, 2026, coinciding with the QMSR implementation date. 

What Should Manufacturers Do Now?

1. Audit Your Quality System: 
   Conduct a gap analysis against ISO 13485:2016 and QMSR to ensure readiness for February 2026. 

2. Update Internal Documentation: 
   Prepare updates to existing SOPs, work instructions, and the Quality Manual to replace references to “QSR” to “QMSR”, with the intention to formally release these updates with an effective date of February 2, 2026. 

3. Review Device Classifications: 
   Confirm exemptions for Class I devices and ensure compliance with recordkeeping under § 820.35. 

4. Prepare for Design and Development Requirements: 
   For Class II and III devices, verify that design documentation aligns with § 820.10(c). 

5. Train Your Teams: 
   Educate regulatory, quality, and engineering staff on QMSR terminology and structure. 

This FDA Technical Amendments QMSR update is part of a broader effort to modernize and harmonize device quality requirements with international standards. Although these changes are editorial, they signal the final phase of the transition from QSR to QMSR. Manufacturers should use this time to audit their quality systems and ensure readiness for the February 2026 compliance date.

Learn More About the MedEnvoy’s QMS Consulting Support Services  

MedEnvoy’s consulting experts can assist manufacturers requiring consulting for FDA Regulatory Inspections and ISO 13485 Audits as well as provide other QMS-related consulting services. Please reach out should you need assistance by clicking here and for information about our QMS consulting support services click here.